Page last updated: 2024-10-16

quinacrine and Neuroblastoma

quinacrine has been researched along with Neuroblastoma in 15 studies

Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.

Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)

Research Excerpts

ExcerptRelevanceReference
"A clone of murine neuroblastoma (N1E-115) was shown to have functional receptors for the nonapeptide bradykinin."7.67Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115). ( Richelson, E; Snider, RM, 1984)
"We previously reported that quinacrine inhibited the formation of an abnormal prion protein (PrPres), a key molecule in the pathogenesis of transmissible spongiform encephalopathy, or prion disease, in scrapie-infected neuroblastoma cells."3.72Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. ( Doh-Ura, K; Ishikawa, K; Iwaki, T; Kawatake, S; Kira, J; Murakami-Kubo, I; Ohta, S; Sasaki, K, 2004)
"The activation of protein kinase C was investigated in digitonin-permeabilized human neuroblastoma SH-SY5Y cells by measuring the phosphorylation of the specific protein kinase C substrate myelin basic protein4-14."3.68Activation of protein kinase C in permeabilized human neuroblastoma SH-SY5Y cells. ( Larsson, C; Mau, S; Saermark, T; Simonsson, P, 1992)
"Quinacrine altered the equilibrium binding of the muscarinic antagonist quinuclidinyl benzilate (QNB) to the muscarinic receptor in membranes from N18TG2 neuroblastoma cells."3.68Muscarinic receptor binding is inhibited by quinacrine. ( Howlett, AC; O'Donnell, KA, 1991)
"A clone of murine neuroblastoma (N1E-115) was shown to have functional receptors for the nonapeptide bradykinin."3.67Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115). ( Richelson, E; Snider, RM, 1984)
"Treatment with quinacrine did not prolong the survival times of prion-inoculated, wild-type or MDR(0/0) mice compared to untreated mice."1.35Continuous quinacrine treatment results in the formation of drug-resistant prions. ( Ahn, M; DeArmond, SJ; Ghaemmaghami, S; Giles, K; Legname, G; Lessard, P; Prusiner, SB, 2009)
"Indomethacin was without effect in modifying the response."1.27Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins. ( Fenton, JW; McKinney, M; Richelson, E; Snider, RM, 1984)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19904 (26.67)18.7374
1990's4 (26.67)18.2507
2000's5 (33.33)29.6817
2010's0 (0.00)24.3611
2020's2 (13.33)2.80

Authors

AuthorsStudies
May, BC2
Witkop, J1
Sherrill, J1
Anderson, MO1
Madrid, PB1
Zorn, JA1
Prusiner, SB3
Cohen, FE2
Guy, RK1
Rank, L1
Puhl, AC1
Havener, TM1
Anderson, E1
Foil, DH1
Zorn, KM1
Monakhova, N1
Riabova, O1
Hickey, AJ1
Makarov, V1
Ekins, S1
Biggi, S1
Pancher, M1
Stincardini, C1
Luotti, S1
Massignan, T1
Dalle Vedove, A1
Astolfi, A1
Gatto, P1
Lolli, G1
Barreca, ML1
Bonetto, V1
Adami, V1
Biasini, E1
Ghaemmaghami, S1
Ahn, M1
Lessard, P1
Giles, K1
Legname, G1
DeArmond, SJ1
Murakami-Kubo, I1
Doh-Ura, K2
Ishikawa, K1
Kawatake, S1
Sasaki, K1
Kira, J1
Ohta, S1
Iwaki, T2
Snider, RM2
McKinney, M1
Fenton, JW1
Richelson, E2
Murato, K1
Monard, D1
Lee, RK1
Wurtman, RJ1
Cox, AJ1
Nitsch, RM1
Ray, R1
Legere, RH1
Majerus, BJ1
Petrali, JP1
Caughey, B1
Korth, C1
Larsson, C1
Saermark, T1
Mau, S1
Simonsson, P1
O'Donnell, KA1
Howlett, AC1
Inoue, S1
Ravindranath, Y1
Ottenbreit, MJ1
Thompson, RI1
Zuelzer, WW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092]Phase 269 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Change in Phonemic Fluency (Words Beginning With Letter D)"

"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-2.4
Quinacrine-2.2

ADAS-Cog Change After 2 Months Among Survivors

ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo13.0
Quinacrine12.6

Barthel Score Change After 2 Months

An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months

Interventionunits on a scale (Mean)
Placebo-23.2
Quinacrine-13.2

Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months

Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo3.2
Quinacrine0.3

Change in Mini-Mental State Examination (MMSE) After 2 Months

The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2

Interventionunits on a scale (Mean)
Placebo-6.9
Quinacrine-3.9

Change in Rankin Score After 2 Months

"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo0.8
Quinacrine0.3

Change in Semantic Verbal Fluency (Naming Animals)

Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-3.2
Quinacrine-2.2

Primary Survival

Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2

Interventionparticipants (Number)
Placebo19
Quinacrine13

Other Studies

15 other studies available for quinacrine and Neuroblastoma

ArticleYear
Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells.
    Bioorganic & medicinal chemistry letters, 2006, Sep-15, Volume: 16, Issue:18

    Topics: Aminacrine; Cell Line; Cell Survival; Humans; Molecular Structure; Neuroblastoma; Scrapie; Structure

2006
Multiple approaches to repurposing drugs for neuroblastoma.
    Bioorganic & medicinal chemistry, 2022, 11-01, Volume: 73

    Topics: Bayes Theorem; Cell Line, Tumor; Child; Child, Preschool; Crizotinib; Drug Repositioning; Etoposide;

2022
Identification of compounds inhibiting prion replication and toxicity by removing PrP
    Journal of neurochemistry, 2020, Volume: 152, Issue:1

    Topics: Animals; Casein Kinase II; Cell Line, Tumor; Cell Membrane; Cell Survival; Drug Evaluation, Preclini

2020
Continuous quinacrine treatment results in the formation of drug-resistant prions.
    PLoS pathogens, 2009, Volume: 5, Issue:11

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4;

2009
Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies.
    Journal of virology, 2004, Volume: 78, Issue:3

    Topics: Animals; Brain; Humans; Immunohistochemistry; Injections, Intraventricular; Mice; Mice, Transgenic;

2004
Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins.
    The Journal of biological chemistry, 1984, Jul-25, Volume: 259, Issue:14

    Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Antioxidants; Catechols; Cell Line; Cyclic GMP; Humans; In

1984
Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115).
    Journal of neurochemistry, 1984, Volume: 43, Issue:6

    Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Bradykinin; Calcium; Catechols; Cell Line; Clone Cells; Cy

1984
Inhibition of S-adenosylmethionine-linked methylation can lead to neurite extension in neuroblastoma cells.
    FEBS letters, 1982, Aug-02, Volume: 144, Issue:2

    Topics: Animals; Calcimycin; Clone Cells; Methylation; Mice; Neoplasms, Experimental; Neuroblastoma; Neurons

1982
Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors.
    Proceedings of the National Academy of Sciences of the United States of America, 1995, Aug-15, Volume: 92, Issue:17

    Topics: Alanine; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line; Chelating Agents

1995
Sulfur mustard-induced increase in intracellular free calcium level and arachidonic acid release from cell membrane.
    Toxicology and applied pharmacology, 1995, Volume: 131, Issue:1

    Topics: Animals; Arachidonic Acid; Calcium; Cell Membrane; Cell Survival; Glioma; Glutathione; Hybrid Cells;

1995
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.
    Journal of virology, 2000, Volume: 74, Issue:10

    Topics: Animals; Cysteine Proteinase Inhibitors; Inhibitory Concentration 50; Leucine; Lysosomes; Neuroblast

2000
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Aug-14, Volume: 98, Issue:17

    Topics: Acridines; Animals; Cells, Cultured; Chlorpromazine; Fatty Acids; Humans; Mice; Neuroblastoma; Pheno

2001
Activation of protein kinase C in permeabilized human neuroblastoma SH-SY5Y cells.
    Journal of neurochemistry, 1992, Volume: 59, Issue:2

    Topics: Acetophenones; Amino Acid Sequence; Arachidonic Acids; Calcium; Cell Membrane; Cell Membrane Permeab

1992
Muscarinic receptor binding is inhibited by quinacrine.
    Neuroscience letters, 1991, Jun-10, Volume: 127, Issue:1

    Topics: Binding, Competitive; Calcium; Carbachol; Cyclic AMP; Muscarinic Antagonists; Neuroblastoma; Quinacr

1991
Chromosomal analysis of metastatic retinoblastoma cells.
    Humangenetik, 1974, Volume: 25, Issue:2

    Topics: Bone Marrow Cells; Cerebrospinal Fluid; Child, Preschool; Chromosome Aberrations; Humans; Karyotypin

1974